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Abstract: Fucoidans are multifunctional marine macromolecules that are subjected to numerous and
various downstream processes during their production. These processes were considered the most
important abiotic factors affecting fucoidan chemical skeletons, quality, physicochemical properties,
biological properties and industrial applications. Since a universal protocol for fucoidans production
has not been established yet, all the currently used processes were presented and justified. The current
article complements our previous articles in the fucoidans field, provides an updated overview
regarding the different downstream processes, including pre-treatment, extraction, purification and
enzymatic modification processes, and shows the recent non-traditional applications of fucoidans in
relation to their characters.
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1. Introduction
Polysaccharides, nucleic acids, and peptides are considered the main three types of bioactive
polymeric macromolecules [1]. Among these, polysaccharides serve various roles in living cells
including structural functions, where cellulose and chitin represent the major components of the
different cell wall matrices [2,3], energy storage (e.g., starch and glycogen) [4,5], and hydration and
signaling functions (e.g., mucilage and alginic acid) [6,7].
Particularly, marine homo- and heteropolysaccharides are derived from marine organisms,
which represent a large part of global biodiversity [8]. Among these are the algal polysaccharides,
such as fucoidan and alginate in brown seaweeds, carrageenan in red seaweeds and ulvan in green
seaweeds. These were reported to have interesting nutraceutical, biomedical, pharmaceutical and
cosmeceutical applications, including dietary fibers; anti-inflammatory, anti-tumor, anti-oxidant,
hepatoprotective and anti-coagulant properties; and drug carrier functionality. Therefore, they have
been extensively investigated during the last few decades [9–13], especially after the emergence of
glycobiology and glycomics [14–17].
Polysaccharides such as dietary fibers of brown algae are abundant and diverse (e.g., alginates,
cellulose, fucoidans and laminarins) constituting the major components (up to 75%) of the dried
thallus weight (% DW) [18–20]. Previous work investigated their abundance in different species,
reporting Fucus, Ascophyllum, Saccharina, and Sargassum to contain 65.7, 69.6, 57.8 and 67.8 % DW,
respectively [21,22]. Specifically, fucoidans are found in the cell walls and extracellular matrices
of brown algae in addition to more than 265 genera and 2040 species of marine invertebrates (e.g.,
sea cucumbers), where they perform vital structural functions [23–26]. Fucoidans are assumed to act
as cross-linkers between the major threads of cellulose and hemicellulose, promoting cellular integrity
and maintaining cellular hydration (especially during drought seasons) [27]. They also act in other
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reproductive, immune and cell-to-cell communicative roles [23]. As recommended by the International
Union of Pure and Applied Chemistry (IUPAC), fucoidans is a general term used to describe sulfated
L-fucose-based polymers including sulfated fucans cited by the Swedish scholar Kylin, as well as other
fucose-rich sulfated heteropolysaccharides [23,28]. Their chemical structures, in terms of monomeric
composition and branching, are quite simple in marine invertebrates compared to their analogues in
brown algae [13,29].
Hundreds of articles have thoroughly discussed and reviewed the biological, pharmacological
and pharmaceutical applications of fucoidans [30–33], including nanomedicine, [34] which has made it
a hot topic in the last few decades [35–37]. All these studies tried to investigate fucoidans molecular
mechanisms in relation to their chemical structure and physicochemical properties. Therefore, different
hypotheses were suggested for each activity, such as anti-tumor [31,38–40], anti-coagulant [41,42],
anti-viral [43,44] and anti-inflammatory activity[45,46]. These investigations revealed that various
factors are relevant, such as molecular weight, sulfation pattern, sulfate content and monomeric
composition [47–49]. For example, different fractions were produced with different physicochemical
properties in our previous experiments; sulfation pattern and sulfate content were highly related to
anti-viral and cytotoxic activities against HSV-1 and Caco-2 cell lines, respectively, while molecular
weight and sugar composition were potential factors in anti-coagulation activity [41,50]. In addition,
degree of purity was reported as an influential factor [32], where co-extracted contaminants (e.g.,
phlorotannins or polyphenols) could lead to significant interference in anti-oxidant activity and,
consequently, cosmetic applications [51,52].
Therefore, several key production challenges regarding fucoidans were discussed in our last
review article in order to obtain a product that follows the universal good manufactured practice (GMP)
guidelines. The article discussed sources of heterogeneity in extracted fucoidans, including the different
biotic (e.g., biogenic, geographical and seasonal factors) and abiotic (e.g., downstream processes) factors
affecting the fucoidans physicochemical and chemical properties [53]. Others patented production
techniques that have assisted in the marketing of several commercial fucoidans by well-known
companies (e.g., Sigma-Aldrich®, Algues and Mer and Marinova®) derived from Fucus vesiculosus and
other brown algae species [54–56].
Furthermore, the improvement of fucoidans activity was investigated, targeting several points.
Among these was the modification of the chemical structure of the native fucoidans scaffolding,
including depolymerization [57,58] and over-sulfation [59]. These modifications could be attempted
chemically [60], enzymatically [35,61] or physically [62]. Predetermined synthesis of oligomers [63,64]
and low molecular weight polymers with defined monomeric units [65] is also involved. Additionally,
fractionation of fucoidans is a common approach during extraction and purifications steps by applying
different extraction and purification conditions (e.g., pH, time, molarity of NaCl) [49,55].
The current article aimed at complementing our previously published article discussing the
reasons for heterogeneity of fucoidans [53]. It reviewed and evaluated the different downstream
processes used in production as the most important abiotic factors affecting the fucoidans quality and
structural features; it then addressed recent uncommon applications and prospective bioproduction
of fucoidans. In addition, the updated status of enzymatic structural modifications of fucoidans,
especially by fucoidanases, were presented.
2. Global Market and Cultivation of Brown Algae
Marine hydrocolloids (e.g., agar, carrageenan and alginate) are of particular industrial interest,
with worldwide annual production of approx. 100,000 tons and a value above US $1.1 billion [66].
Based on FAO periodical reports (FAO, 2014, 2016), among the top seven most-cultivated seaweeds,
three taxa are mainly used for hydrocolloids production; these include Rhodophyta (e.g., Eucheuma sp.
and Kappaphycus alvarezii) for carrageenan production and Gracilaria sp. for agar production [67].
These data encouraged the global marine market to escalate the production yield by finding alternative,
eco-friendly seaweed cultivation techniques, such as sea farming or aquaculture and biotechnology [53].
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In 2014, the annual production of cultivated seaweeds reached 27.3 million tons [68], representing 27%
of the total marine aquaculture production, while the global market of marine biotechnology (blue
biotechnology) for industrial applications has been expected to achieve US $4.8 billion in 2020 and
grow to US $6.4 billion by 2025 [69].
Species of brown macroalgae (Phaeophyceae) are distributed among the orders Fucales and
Laminariales, which are the major commercial sources of the algal sulfated polysaccharides, in addition
to Chordariales, Dictyotales, Dictyosiphonales, Ectocarpales, and Scytosiphonales. Moreover,
phylogenetic analysis showed that Fucales are one of the largest and most diversified orders within
Phaeophyceae, having eight families (41 genera and 485 species), named Ascoseiraceae, Cystoseiraceae,
Durvillaeaceae, Fucaceae, Hormosiraceae, Himanthaliaceae, Sargassaceae, and Seirococcaceae [70].
Figure 1 illustrates the distribution of several examples of well-known brown algae species which are
considered potential sources of sulfated polysaccharides dominating tropical to temperate marine
forests and intertidal regions. The data were based on Wahl, et al. [71].
Figure 1. Global distribution of the major brown seaweeds’ species. They dominate tropical to
temperate marine forests and intertidal regions.
Furthermore, like terrestrial plant tissue culture (PTC), several biotechnological attempts were
performed to cultivate and/or regenerate thallus from different species of brown seaweeds using
seaweeds tissue culture [72]. They include micropropagation, callus induction and protoplast
isolation [69,73–75]. They are very promising techniques as it may not only help to overcome the
previously mentioned fucoidans production heterogeneity challenges [53] but also provide a sustainable
supply [76]. However, compared to PTC, STC is still not well-enough established to be used for
production of hydrocolloids and fucoidans [77] or cultivation in closed, well-controlled bioreactors,
as in case of the red algae organism Agardhiella subulata [78].
3. Downstream Processes
Fucoidans are anionic polymers occurring in highly complicated matrices in cell walls and
intercellular spaces along with other carbohydrate polymers (e.g., alginate, cellulose and laminarin),
polyphenols and proteins [79]. Additionally, due to the sulfate ester groups, fucoidans are
water soluble polysaccharide polymers [80] exhibiting high affinity to other cell wall components,
especially polyphenols [81]. Therefore, various and complicated downstream processes are required to
remove such extraneous substances before and after precipitation with ethanol or cationic surfactants
to obtain high-purity fucoidans [82,83]. The processes always include pre-treatment, extraction and
purification stages as shown in Figure 2.
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Figure 2. Required downstream processes including steps in each process for fucoidans production.
3.1. Pre-Treatment
After harvesting algal biomass from beaches, the biomass should be washed thoroughly with
tap water to remove sands and epiphytes, then dried and milled to increase the area-to-mass
ratio. Several pre-treatment steps are performed before the extraction step to release fucoidans
from intercalating components, ease the following extraction process, improve the extraction
yield, and decrease the possible interferences from co-extracted components in purification and
biological investigations.
Previous experiments tried to remove pigments (e.g., chlorophyll, flavins and carotenoids) and
lipids in specific bleaching and defatting steps with acetone, toluene, charcoal or 80%–85% (v/v)
ethanol [34,84,85]. Since fucoidans are negatively charged molecules, they remained unaffected by
incubation with organic solvents (e.g., acetone, toluene or hexane:isopropanol (3:2) mixture) during
pre-treatment of the dried algal biomass. Such extracts were further treated to obtain carotenoids,
represented by fucoxanthin in brown algae [86], lipids and fatty acid metabolites (especially essential
polyunsaturated fatty acids (PUFA) and fucosterol), adding to nutraceutical applications of brown
algae [87,88]. In contrast, activated carbon materials, such as charcoal, adsorb the target fucoidans
molecules, adversely affecting the final production yield [79].
Other studies tried to exclude the tightly non-covalently bound polyphenolic compounds
represented by phloroglucinol-type phlorotannins [89], which contribute to the light to dark brown
color of the crude fucoidans extract (along with fucoxanthin) [41,81]. They reported comparatively
high phlorotannins content, reaching approximately one fifth of the brown algae dry weight [25].
Phlorotannins perform major structural and physiological functions, like tannins found in plants,
including defense against biotic and abiotic stresses [90,91]. Despite of the great pharmacological
importance of phlorotannins [92,93], their presence in high-quality fucoidans is not acceptable because of
the possibility of interference with the anti-oxidant [25,52,94] and anti-tumor activities of fucoidans [95].
Therefore, the natural phenolics content of fucoidans should be determined before the measurement of
their biological activities [96]. Therefore, nearly all pre-extraction protocols for fucoidans involved
strategies to remove such contaminants, e.g., incubation with EtOH:H2O:HCHO (16:3:1) (v/v/v) at
pH 2. Under such conditions, formaldehyde enhances the crosslinking and polymerization of such
polyphenolic contaminants and the high volume of ethanol results in protein denaturation [41,60,97,98].
However, the toxicity of formaldehyde limits its utilization in pre-treatment protocols [51].
Furthermore, pre-treatment steps are performed to remove other carbohydrates such as alginate,
the major hydrocolloids in brown algae [99]. This is commonly removed by formation of water-insoluble
calcium complex either before [60] or during the extraction procedure using 1%–4% (w/v) CaCl2 followed
by a filtration or centrifugation step to remove the formed precipitate [58,98,100,101]. These previously
mentioned procedures were optimized using successive incubation, centrifugation or filtration,
washing and drying for the main extraction step of the dried, milled algal biomass, as described
in Figure 3. The application of such an optimized protocol resulted in a dried, pre-treated powder
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representing 71% (w/w) of the starting material [98]. Despite these results, downstream processing of
fucoidans, except with enzymatic modification, starts with a small scale (e.g., 5–10 g of the dried algal
biomass) to optimize parameters like dried biomass to solvent ratio, temperatures, pH, and incubation
time, based on preliminary quality and yield of crude fucoidans measured by infra-red spectroscopy
(IR), simple sugar tests and elemental analysis. After this, transfer to large scale production could be
accomplished using larger biomass quantities (e.g., 500–1000 g).
Figure 3. Overview of optimized pre-treatment steps of the dried algae biomass before fucoidans
extraction. All steps were performed at 25 ◦C overnight and the ratio between dried algal biomass to
solvent was 1:10, except for the acetone step, which was 1:20 (modified after [98,102]).
Due to several complicated pre-treatment steps, general protocols always employ a single
incubation step using the ternary mixture composed of CH3OH:CH3Cl:H2O (4:2:1) (v/v/v) [103],
binary mixture of CH2Cl2:EtOH (94.2:5.8, v/v) [104], or aqueous ethanol (e.g., 95% v/v) [105,106] to
remove pigments [107], polyphenols [51,103] and lipids [108]. Nevertheless, pre-treatment steps may
be insufficient for complete removal or prevention of some residual co-extraction.
Notably, all these procedures were carried out at room temperature in organic solvents and high
volumes of ethanol, in which fucoidans are insoluble. Theoretically, the native structural backbone
should not be affected. However, similar polymeric carbohydrates such as laminarin may still be
present, contaminating the extract after these steps.
Recently, in order to decrease pollution of organic toxic solvents, compressional-puffing
pre-treatment was applied for Sargassum hemiphyllum and S. glaucescens fucoidans. The pre-treatment
method was based on mechanical pressure at higher temperatures that loosen the cell wall matrix
before the step of extraction. Such methods succeeded in increasing the production yield, but they
affected the molecular features of the fucoidans, including molecular weight [109,110].
3.2. Extraction
As previously mentioned, fucoidans are principally anionic water-soluble macromolecules.
Therefore, they can be extracted from the pre-treated biomass using a simple hot- or cold-water
incubation. Afterwards, the extracted fucoidans can be precipitated by high volumes of solvents with
a low dielectric constant (e.g., >70% (v/v), > 2.5 volume ethanol [111,112], <2 volume acetone [113])
or cationic surfactants (e.g., hexadecyltrimethylammonium bromide (Cetavlon®) 10% (v/v)) [55] via
an affinity complex formation at low temperatures (4 ◦C) to remove the undesired salts from the
sulfated polysaccharides [52]. This specific precipitation reaction between fucoidans and Cetavlon® is
applied in screening tests of microorganisms for putative fucoidanase activity [114].
Ale et al. published comprehensive articles discussing the history of extraction, including the
different classical extraction methods of fucoidans, and reported that extraction procedures significantly
affect the polymers monomeric composition, even for the same organism [60,115]. Beyond simple
hot water extraction [58,116], attempts were made to increase the selectivity and extraction yields,
including extraction in acidic [117], alkaline [118], and buffered [41,119] aqueous solutions. However,
a neutralization step is required, using Na2CO3 or (NH4)2CO3, directly after extraction to guard against
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the non-specific acidic hydrolysis of the polymer [101,115]. Such drastic pH changes affect the chemical
and physicochemical properties of fucoidans during the extraction step.
Currently, besides the previously discussed classical extraction methods based on thermal energy,
extraction protocols based on vibrational energy have been developed. These protocols are based on
microwave-assisted (MAE) [120,121] or ultrasound-assisted (UAE) [94,122] extraction steps to elicit
cell wall degradation which improves the polymer release into aqueous solvent. These protocols
were optimized either using an approach that modified one factor at a time or a multiple factorial
design, setting the polymers production yield, monomeric composition and biological activities as the
measured responses.
Recently, combined sulfated polysaccharides extraction protocols were optimized from different
brown algae species using hydrothermal-assisted extraction (HAE) followed by sequential ultrasound
and thermal technologies [123]. Similarly, subcritical water extraction was applied to increase the
production yield of fucoidans from Nizamuddinia zanardinii [124]; such mild conditions may be
advantageous to preserve the native chemical backbone and physicochemical characters of fucoidans.
Recently, as a trial to reduce such undesirable effects, enzyme-aided or assisted extraction
(EAE) protocols are being developed using enzymes instead of harsh chemicals and high extraction
temperatures during extraction. These include cellulase, papain, laminarinase, alginate lyase,
and protease, which are present in products of Novozymes [79,125–128]. In addition, other cost-effective
and time-saving techniques are reported, like those for terrestrial plant polysaccharides, such as
extraction under vacuum to lower the boiling point of water and hence avoid possible heat-induced
fucoidans degradation [129]. Alternatively, 0.5% (w/v) ethylenediaminetetraacetic acid (EDTA)
was applied at 70 ◦C for simultaneous extraction of Laminaria japonica fucoidans and removal
of pigments [130].
3.3. Separation Physical Methods
Filtration, dialysis and centrifugation, either for the algal biomass or precipitates, are also among
the downstream processes after pre-treatment and extraction steps [131–133]. Cross-flow filtration
and dialysis against water are usually performed using different molecular weight cut-off (MWCO)
membranes for isolation of fucoidans from smaller compounds depending on the high molecular
weight of fucoidans [134] and also for fractionation purposes, where low molecular weight fucoidans
(LMWF) can be separated from high molecular weight analogues (HMWF) [49].
In addition, filtration, concentration, and fractionation are simultaneously performed using
centrifugal concentrators (Vivaspin®) equipped with membranes with certain MWCO, like in protein
purification. However, in some cases, especially in the presence of bulk masses or high concentrations of
salts and small contaminants, the use of centrifugal concentrators becomes practically and economically
unsuitable for fucoidans purification. In such cases, bulky contaminants result in membrane clogging
leading to its deterioration and increasing the production cost.
3.4. Purification
Despite the previously mentioned purification steps, residuals of co-extracted contaminants are
still present, and resulting fucoidans are still crude-type. [27]. Therefore, further selective purification
steps are needed to obtain a high-quality product for reproducible and accurate biological investigations.
Some researches adopted simple, non-chromatographic steps, such as bleaching of the crude fucoidans
(NaClO2 in dilute HCl) followed by precipitation with cetyltrimethylammonium bromide [135] or
by cold overnight incubation in aqueous buffered solution of calcium acetate (20 mM, pH = 6.5
-7.5) followed by dialysis [136]. In addition, membrane filtration was reported to produce fucoidans
fractions of different molecular weight [137].
However, other chromatographic purification techniques were discussed in our previous
publications [41,53,98,102]. Almost all the chromatographic techniques are based on the permanent
negatively charged sulfate ester groups distributed on the polymer backbone which allow selective
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fucoidans capture. However, carboxylated (e.g., alginate) and phosphorylated (e.g., nucleic acids)
compounds might interfere [138,139]. Therefore, the pH value of the applied solvents is critical during
chromatographic purification. One option for this uses anionic exchange resins (e.g., diethylaminoethyl
cellulose or DEAE-cellulose), which was performed at pH 7.2 using 0.1 M sodium phosphate
buffer [140]. An alternative is cationic dyes (e.g., toluidine blue- or perylene diimide derivative),
modified resins or chitosan functioning in buffered solutions [27,102]. Both anion exchange and dye
affinity chromatography involve the use of highly concentrated NaCl elution solvents. As a result,
a subsequent purification step using chromatographic gel permeation [141] or dialysis [140] is required
to remove salts, increasing the production costs. Other methods based on the use of biological
macromolecules, such as lectins and anti-thrombin III, were also reported [53].
Novel innovative purification techniques were recently developed, such as selective solid phase
extraction for purifying fucoidans and other complex seaweeds polymers by molecularly imprinted
polymers (MIP) [142,143] or MIP modified by deep eutectic solvents [142,143]. Abdella et al.,
developed a green and time-saving purification protocol using genipin cross-linked toluidine blue
immobilized-chitosan beads employing fucoidans affinity to cationic thiazine dyes [102].
4. Recent Uncommon Applications
In addition to the classical therapeutic applications of fucoidans, including anti-coagulant [41,144],
anti-viral [145,146], anti-inflammatory [46,147] and selective cytotoxic and anti-tumor uses [39,50],
uncommon bioactivities, including cosmeceutical, pharmaceutical, diagnostic, and synergistic
therapeutic applications were recently reported [32]. Recent fucoidans uses included therapeutic
treatment of major blindness diseases [148]. It has also been used as a drug carrier, especially for
anti-cancer treatments and anti-biotics. Additionally, fucoidans have been shown to improve drug
bioavailability and efficacy in pharmaceutical formulations, including in nanoparticles, liposomes,
microparticles, and semisolid formulations [28,149,150]. Table 1 summarizes some of the recent and
uncommon fucoidans applications based on in-vitro or in-vivo studies, in addition to biogenic resources
and physicochemical features.
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Table 1. Some selected recent therapeutic, diagnostic and pharmaceutical applications of fucoidans
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5. Enzymatic Modification of Native Fucoidans
Owing to their high molecular weight, therapeutic applications of native fucoidans face many
challenges including structure elucidation, solubility, manufacturing, and handling [63,116], in addition
to safety as a food supplement [175]. Structure elucidation and quantitation of native fucoidans is highly
complicated and requires advanced or hyphenated spectroscopic techniques such asHPLC-MS/MS as
it applied in Sea Cucumbers fucoidans [176,177]. Also, these techniques must be applied after a step of
enzymatic or acid hydrolysis to transform the fucoidans polymers to oligomers. According to their
molecular weight, fucoidans are classified into three classes: LMWF (<10 kDa), medium molecular
weight fucoidan (MMWF) (10–10000 kDa), and HMWF (>10000 kDa) [31]. LMWF demonstrated
better bioavailability and bioactivities than HMWF [178,179]. As a consequence, several articles
reported physical, chemical and enzymatic modification of the native HMWF to get LMWF of
higher biological activity [62]. Specifically, enzymatic modification of macroalgal polysaccharides,
including fucoidans by either fucoidanases or sulfatases, is characterized by regioselectivity and
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stereospecificity. This new trend is considered crucial and highly promising for current and future
applications of polysaccharides [180].
Nevertheless, our publications in 2009 particularly reviewed the specific enzymatic degradation
of fucoidans induced by fucoidanases (EC 3.2.1.44) and α-L-fucosidases (EC 3.2.1.51), mainly those
isolated from marine bacteria [35]. Cumashi, et al. studied the chemical structures of different
fucoidans isolated from a number of brown algal species [181]. Their proposed models, which were
highly appreciated and recommended by many researchers [60], showed the backbone of fucoidans
to be mainly an alternating α-(1-4) and α-(1-3) linked L-fucopyranoside. Regarding the sulfation
pattern, C-2 is usually substituted with sulfate ester groups in addition to alternating C-3 or C-4 in
L-fucopyranose residue, according to the glycosidic linkages. In addition, branched chain polymers
were also found as in F. serratus. Other minor sugar units (e.g., mannose, galactose, glucose and
xylose) occur as well in fucoidans structure; however, their distribution pattern and positions are still
unknown [60,181]. Now, the mechanism of enzymatic degradation can be described in relation to
fucoidans chemical structures.
Despite the increasing number of publications investigating fucoidanase activity of different marine
species cell extracts, few of these enzymes have been isolated and characterized. Moreover, genome
sequences encoding few fucoidanases have been published, including Ffa2 and FFA1 from Formosa algae
KMM 3553T [182,183], FcnA from Mariniflexili fucanivorans SW5T [184]. Therefore, specificity of fucoidanases,
type of cleaved glycoside bond, structure-activity relationship studies and enzyme stability are still poorly
described. It was only observed that identified microbial fucoidanses act only on fucoidans isolated from
their respective symbionts [185]. In fact, fucoidanases have not actually been fully utilized yet as a powerful
tool either for the structural studies of fucoidans or production of defined and well-characterized bioactive
fragments of extracted fucoidans, as shown in Table 2.
Similarly, recent advances in bioinformatics and genome sequencing of microbial species have
resulted in a continual increase of novel genome sequences. These genomes demonstrated various
potential genes encoding for enzymes with biopolymer-degrading capabilities, such as Shewanella
violacea DSS12 (NC_014012.1), Formosa algae KMM 3553 (NZ_LMAK01000014.1) [182], Formosa haliotis
MA1 (NZ_BDEL01000001.1) [198], Wenyingzhuangia fucanilytica CZ1127 (NZ_CP014224.1) [199] and
Pseudoalteromonas sp. strain A601 (MXQF01000000) [200]. Moreover, production of stabilized
fucoidanases has been achieved by targeted truncation of the C-terminal of FcnA2, Fda1 and
Fda2. This recently developed method may help with enzymatic production of defined degrees
of polymerization and more bioactive products from native fucoidan substrates [201].
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Table 2. Source of fucoidans as a substrate and mode of action of some fucoidanases.
Biogenic Source of
Fucoidans Fucoidanase Source Mode of Action Ref.
F. evanescens
Formosa algae KMM 3553 Endo
α-1→4 [61,182]
Pseudoalteromonas citrea




F. vesiculosus Dendryphiella. arenaria TM94 Endon.d. * [187]







Flavobacterium sp. F-31 Endon.d. [190]
F. distichus Littorina kurila Endo
α-1→3 [191]
Pelvetia canaliculata Mariniflexile fucanivorans SW5T
Endo
α-1→4 [184]
Undara pinnatifida Sphingomonas paucimobilis PF-1 Endon.d. [192,193]
Saccharina cichorioides
Pseudoalteromonas citrea




Nemacystus decipiens Mizuhopecten yessoensis Endon.d. [194]
Ascophyllum nodosum Pecten maximus Exon.d. [195,196]
Thelenota ananas (Wild
sea cucumber) Wenyingzhuangia Fucanilytica
Endo
n.d. [197]
* n.d.: not determined.
6. Conclusion and Future Prospective
As multifunctional molecules, fucoidans have received special interest based on their proven
efficacy in different fields. The current article reviewed many aspects related to fucoidans’ production,
mainly from brown algae. Biogenic source and downstream processes were shown as major
factors determining their application, which is affected by molecular weight and quality grade
of fucoidans. Therefore, the alteration of fucoidans’ native structure was recommended, especially as
performed by fucoidanases. Their production in nanoform or in combination with other polymers can
improve or modify their potential uses, allowing their expanded potential as therapeutic agents, e.g.,
in anti-cancer applications [202].
Production of high-quality purified fucoidans is urgently required to clarify the relationships
between chemical structure and the various bioactivities attributed to fucoidans, eliminating any
interference from contaminants. However, it was observed in some cases that crude extracts and
presence of co-extracted contaminants, especially polyphenolic phlorotannins, have advantageous
cosmeceutical effects due to their powerful anti-oxidant activity [203,204].
Novel techniques, either in cultivation or downstream processes, have been established,
increasing the global production yields and reducing ecological and economic problems. A new
advance toward achieving such goals was established by optimization of water extraction via
measurement of kinetic parameters [205]. In addition to this, it is expected that most future trends
in marine biotechnology research will focus on the cell wall and extracellular matrix components of
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brown algae, including fucoidans’ biosynthetic genes and production regulators [23,53,63,206–208].
Such trials may enable the scientific community to produce more bioactive molecules of fucoidans
with defined characteristics, including degree of polymerization, sulfate content and pattern,
in reproducible manners.
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brown algae (Pheophyceae) species: Extraction, identification, and quantification. Biomolecules 2019, 9, 244.
[CrossRef] [PubMed]
26. Chang, Y.; Xue, C.; Tang, Q.; Li, D.; Wu, X.; Wang, J. Isolation and characterization of a sea cucumber
fucoidan-utilizing marine bacterium. Lett. Appl. Microbiol. 2010, 50, 301–307. [CrossRef]
27. Zayed, A.; Dienemann, C.; Giese, C.; Krämer, R.; Ulber, R. An immobilized perylene diimide derivative for
fucoidan purification from a crude brown algae extract. Process Biochem. 2018, 65, 233–238. [CrossRef]
28. Citkowska, A.; Szekalska, M.; Winnicka, K. Possibilities of fucoidan utilization in the development of
pharmaceutical dosage forms. Mar. Drugs 2019, 17, 458. [CrossRef]
29. Li, S.; Li, J.; Zhi, Z.; Hu, Y.; Ge, J.; Ye, X.; Tian, D.; Linhardt, R.J.; Chen, S. 4-O-sulfation in sea cucumber
fucodians contribute to reversing dyslipidiaemia caused by HFD. Int. J. Biol. Macromol. 2017, 99, 96–104.
[CrossRef]
30. Fitton, J.H.; Stringer, D.S.; Park, A.Y.; Karpiniec, S.N. Therapies from fucoidan: new developments. Mar. Drugs
2019, 17, 571. [CrossRef]
31. Van Weelden, G.; Bobinski, M.; Okla, K.; van Weelden, W.J.; Romano, A.; Pijnenborg, J.M.A. Fucoidan
structure and activity in relation to anti-cancer mechanisms. Mar. Drugs 2019, 17, 32. [CrossRef] [PubMed]
32. Wang, Y.; Xing, M.; Cao, Q.; Ji, A.; Liang, H.; Song, S. Biological activities of fucoidan and the factors
mediating its therapeutic effects: A review of recent studies. Mar. Drugs 2019, 17, 183. [CrossRef] [PubMed]
33. Luthuli, S.; Wu, S.; Cheng, Y.; Zheng, X.; Wu, M.; Tong, H. Therapeutic effects of fucoidan: A review on
recent studies. Mar. Drugs 2019, 17, 487. [CrossRef] [PubMed]
34. Chollet, L.; Saboural, P.; Chauvierre, C.; Villemin, J.N.; Letourneur, D.; Chaubet, F. Fucoidans in nanomedicine.
Mar. Drugs 2016, 14, 145. [CrossRef] [PubMed]
35. Holtkamp, A.D.; Kelly, S.; Ulber, R.; Lang, S. Fucoidans and fucoidanases-focus on techniques for molecular
structure elucidation and modification of marine polysaccharides. Appl. Microbiol. Biotechnol. 2009, 82, 1–11.
[CrossRef] [PubMed]
36. Ustyuzhanina, N.E.; Bilan, M.I.; Ushakova, N.A.; Usov, A.I.; Kiselevskiy, M.V.; Nifantiev, N.E. Fucoidans:
Pro- or antiangiogenic agents? Glycobiology 2014, 24, 1265–1274. [CrossRef]
37. Zhao, Y.; Zheng, Y.; Wang, J.; Ma, S.; Yu, Y.; White, W.L.; Yang, S.; Yang, F.; Lu, J. Fucoidan extracted from
Undaria pinnatifida: Source for nutraceuticals/functional foods. Mar. Drugs 2018, 16, 321. [CrossRef]
38. Arumugam, P.; Arunkumar, K.; Sivakumar, L.; Murugan, M.; Murugan, K. Anticancer effect of fucoidan
on cell proliferation, cell cycle progression, genetic damage and apoptotic cell death in HepG2 cancer cells.
Toxicol. Rep. 2019, 6, 556–563.
39. Atashrazm, F.; Lowenthal, R.M.; Woods, G.M.; Holloway, A.F.; Dickinson, J.L. Fucoidan and cancer:
A multifunctional molecule with anti-tumor potential. Mar. Drugs 2015, 13, 2327–2346. [CrossRef]
Mar. Drugs 2020, 18, 170 14 of 22
40. Chen, L.-M.; Liu, P.-Y.; Chen, Y.-A.; Tseng, H.-Y.; Shen, P.-C.; Hwang, P.-A.; Hsu, H.-L. Oligo-fucoidan prevents
IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression.
Sci. Rep. 2017, 7, 11864. [CrossRef]
41. Zayed, A.; Muffler, K.; Hahn, T.; Rupp, S.; Finkelmeier, D.; Burger-Kentischer, A.; Ulber, R. Physicochemical
and biological characterization of fucoidan from Fucus vesiculosus purified by dye affinity chromatography.
Mar. Drugs 2016, 14, 79. [CrossRef] [PubMed]
42. Zhao, X.; Dong, S.; Wang, J.; Li, F.; Chen, A.; Li, B. A comparative study of antithrombotic and antiplatelet
activities of different fucoidans from Laminaria japonica. Thromb. Res. 2012, 129, 771–778. [CrossRef]
[PubMed]
43. Wang, W.; Wu, J.; Zhang, X.; Hao, C.; Zhao, X.; Jiao, G.; Shan, X.; Tai, W.; Yu, G. Inhibition of influenza A
virus infection by fucoidan targeting viral neuraminidase and cellular EGFR pathway. Sci. Rep. 2017, 7,
40760. [CrossRef] [PubMed]
44. Prokofjeva, M.M.; Imbs, T.I.; Shevchenko, N.M.; Spirin, P.V.; Horn, S.; Fehse, B.; Zvyagintseva, T.N.;
Prassolov, V.S. Fucoidans as potential inhibitors of HIV-1. Mar. Drugs 2013, 11, 3000–3014. [CrossRef]
[PubMed]
45. Takahashi, H.; Kawaguchi, M.; Kitamura, K.; Narumiya, S.; Kawamura, M.; Tengan, I.; Nishimoto, S.;
Hanamure, Y.; Majima, Y.; Tsubura, S.; et al. An exploratory study on the anti-inflammatory effects of
fucoidan in relation to quality of life in advanced cancer patients. Integr. Cancer Ther. 2018, 17, 282–291.
[CrossRef]
46. Park, H.Y.; Han, M.H.; Park, C.; Jin, C.-Y.; Kim, G.-Y.; Choi, I.-W.; Kim, N.D.; Nam, T.-J.; Kwon, T.K.;
Choi, Y.H. Anti-inflammatory effects of fucoidan through inhibition of NF-κB, MAPK and Akt activation in
lipopolysaccharide-induced BV2 microglia cells. Food Chem. Toxicol. 2011, 49, 1745–1752. [CrossRef]
47. Li, B.; Lu, F.; Wei, X.; Zhao, R. Fucoidan: Structure and bioactivity. Molecules 2008, 13, 1671–1695. [CrossRef]
48. Lu, J.; Shi, K.K.; Chen, S.; Wang, J.; Hassouna, A.; White, L.N.; Merien, F.; Xie, M.; Kong, Q.; Li, J.; et al.
Fucoidan extracted from the New Zealand Undaria pinnatifida-Physicochemical comparison against five other
fucoidans: Unique low molecular weight fraction bioactivity in breast cancer cell lines. Mar. Drugs 2018, 16,
461. [CrossRef]
49. Yoo, H.J.; You, D.-J.; Lee, K.-W. Characterization and immunomodulatory effects of high molecular
weight fucoidan fraction from the sporophyll of Undaria pinnatifida in cyclophosphamide-induced
immunosuppressed mice. Mar. Drugs 2019, 17, 447. [CrossRef]
50. Zayed, A.; Hahn, T.; Finkelmeier, D.; Burger-Kentischer, A.; Rupp, S.; Krämer, R.; Ulber, R. Phenomenological
investigation of the cytotoxic activity of fucoidan isolated from Fucus vesiculosus. Process Biochem. 2019, 81,
182–187. [CrossRef]
51. Imbs, T.I.; Skriptsova, A.V.; Zvyagintseva, T.N. Antioxidant activity of fucose-containing sulfated
polysaccharides obtained from Fucus evanescens by different extraction methods. J. Appl. Phycol. 2015, 27,
545–553. [CrossRef]
52. Hifney, A.F.; Fawzy, M.A.; Abdel-Gawad, K.M.; Gomaa, M. Industrial optimization of fucoidan extraction
from Sargassum sp. and its potential antioxidant and emulsifying activities. Food Hydrocoll. 2016, 54, 77–88.
[CrossRef]
53. Zayed, A.; Ulber, R. Fucoidan Production: Approval Key Challenges and Opportunities. Carbohydr. Polym.
2019, 211, 289–297. [CrossRef] [PubMed]
54. Fitton, J.H.; Stringer, D.N.; Karpiniec, S.S. Therapies from fucoidan: An update. Mar. Drugs 2015, 13,
5920–5946. [CrossRef]
55. Mak, W.; Wang, S.K.; Liu, T.; Hamid, N.; Li, Y.; Lu, J.; White, W.L. Anti-proliferation potential and content of
fucoidan extracted from sporophyll of New Zealand Undaria pinnatifida. Front. Nutr. 2014, 1, 9. [CrossRef]
56. Chauvierre, C.; Aid-Launais, R.; Aerts, J.; Chaubet, F.; Maire, M.; Chollet, L.; Rolland, L.; Bonafe, R.; Rossi, S.;
Bussi, S.; et al. Pharmaceutical development and safety evaluation of a GMP-grade fucoidan for molecular
diagnosis of cardiovascular diseases. Mar. Drugs 2019, 17, 699. [CrossRef]
57. Torres, M.D.; Flórez-Fernández, N.; Simón-Vázquez, R.; Giménez-Abián, J.F.; Díaz, J.F.;
González-Fernández, Á.; Domínguez, H. Fucoidans: The importance of processing on their anti-tumoral
properties. Algal Res. 2020, 45, 101748. [CrossRef]
Mar. Drugs 2020, 18, 170 15 of 22
58. Borazjani, N.J.; Tabarsa, M.; You, S.; Rezaei, M. Improved immunomodulatory and antioxidant properties of
unrefined fucoidans from Sargassum angustifolium by hydrolysis. J. Food Sci. Technol. 2017, 54, 4016–4025.
[CrossRef]
59. Koyanagi, S.; Tanigawa, N.; Nakagawa, H.; Soeda, S.; Shimeno, H. Oversulfation of fucoidan enhances its
anti-angiogenic and antitumor activities. Biochem. Pharmacol. 2003, 65, 173–179. [CrossRef]
60. Ale, M.T.; Mikkelsen, J.D.; Meyer, A.S. Important determinants for fucoidan bioactivity: A critical review of
structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from
brown seaweeds. Mar. Drugs 2011, 9, 2106–2130. [CrossRef]
61. Silchenko, A.S.; Rasin, A.B.; Kusaykin, M.I.; Malyarenko, O.S.; Shevchenko, N.M.; Zueva, A.O.;
Kalinovsky, A.I.; Zvyagintseva, T.N.; Ermakova, S.P. Modification of native fucoidan from fucus evanescens
by recombinant fucoidanase from marine bacteria Formosa algae. Carbohydr. Polym. 2018, 193, 189–195.
[CrossRef] [PubMed]
62. Jiao, G.; Yu, G.; Zhang, J.; Ewart, H.S. Chemical structures and bioactivities of sulfated polysaccharides from
marine algae. Mar. Drugs 2011, 9, 196–223. [CrossRef] [PubMed]
63. Suprunchuk, V.E. Low-molecular-weight fucoidan: Chemical modification, synthesis of its oligomeric
fragments and mimetics. Carbohydr. Res. 2019, 485, 107806. [CrossRef] [PubMed]
64. Kardeby, C.; Fälker, K.; Haining, E.J.; Criel, M.; Lindkvist, M.; Barroso, R.; Påhlsson, P.; Ljungberg, L.U.;
Tengdelius, M.; Rainger, G.E.; et al. Synthetic glycopolymers and natural fucoidans cause human platelet
aggregation via PEAR1 and GPIbα. Blood Adv. 2019, 3, 275–287. [CrossRef]
65. Kasai, A.; Arafuka, S.; Koshiba, N.; Takahashi, D.; Toshima, K. Systematic synthesis of low-molecular weight
fucoidan derivatives and their effect on cancer cells. Org. Biomol. Chem. 2015, 13, 10556–10568. [CrossRef]
66. Rhein-Knudsen, N.; Ale, M.T.; Meyer, A.S. Seaweed hydrocolloid production: An update on enzyme assisted
extraction and modification technologies. Mar. Drugs 2015, 13, 3340–3359. [CrossRef]
67. Buschmann, A.H.; Camus, C.; Infante, J.; Neori, A.; Israel, Á.; Hernández-González, M.C.; Pereda, S.V.;
Gomez-Pinchetti, J.L.; Golberg, A.; Tadmor-Shalev, N.; et al. Seaweed production: Overview of the global
state of exploitation, farming and emerging research activity. Eur. J. Phycol. 2017, 52, 391–406. [CrossRef]
68. Duarte, C.M.; Wu, J.; Xiao, X.; Bruhn, A.; Krause-Jensen, D. Can seaweed farming play a role in climate
change mitigation and adaptation? Front. Mar. Sci. 2017, 4, 100.
69. Zayed, A.; Kovacheva, M.; Muffler, K.; Breiner, H.-W.; Stoeck, T.; Ulber, R. Induction and genetic identification
of a callus-like growth developed in the brown alga Fucus vesiculosus. Eng. Life Sci. 2019, 19, 363–369.
[CrossRef]
70. Cho, G.Y.; Rousseau, F.; de Reviers, B.; Boo, S.M. Phylogenetic relationships within the fucales (Phaeophyceae)
assessed by the photosystem I coding psaa sequences. Phycologia 2006, 45, 512–519. [CrossRef]
71. Wahl, M.; Molis, M.; Hobday, A.J.; Dudgeon, S.; Neumann, R.; Steinberg, P.; Campbell, A.H.; Marzinelli, E.;
Connell, S. The responses of brown macroalgae to environmental change from local to global scales: Direct
versus ecologically mediated effects. Perspect. Phycol. 2015, 2, 11–29. [CrossRef]
72. Crous, P.W.; Wingfield, M.J.; Burgess, T.I.; Hardy, G.S.J.; Gené, J.; Guarro, J.; Baseia, I.G.; García, D.;
Gusmão, L.F.P.; Souza-Motta, C.M.; et al. Fungal planet description sheets: 716–784. Persoonia 2018, 40,
240–393. [CrossRef] [PubMed]
73. Kumar, G.R.; Reddy, C.R.K.; Jha, B. Callus induction and thallus regeneration from callus of phycocolloid
yielding seaweeds from the Indian coast. J. Appl. Phycol. 2007, 19, 15–25. [CrossRef]
74. Muhamad, S.N.S.; Ling, A.P.-K.; Wong, C.-L. Effect of plant growth regulators on direct regeneration and
callus induction from Sargassum polycystum C. Agardh. J. Appl. Phycol. 2018, 30, 3299–3310. [CrossRef]
75. Avila-Peltroche, J.; Won, B.Y.; Cho, T.O. Protoplast isolation and regeneration from Hecatonema terminale
(Ectocarpales, Phaeophyceae) using a simple mixture of commercial enzymes. J. Appl. Phycol. 2019, 31,
1873–1881. [CrossRef]
76. Luiten, E.E.; Akkerman, I.; Koulman, A.; Kamermans, P.; Reith, H.; Barbosa, M.J.; Sipkema, D.; Wijffels, R.H.
Realizing the promises of marine biotechnology. Biomol. Eng. 2003, 20, 429–439. [CrossRef]
77. Baweja, P.; Sahoo, D.; García-Jiménez, P.; Robaina, R.R. Review: Seaweed tissue culture as applied to
biotechnology: Problems, achievements and prospects. Phycol. Res. 2009, 57, 45–58. [CrossRef]
78. Huang, Y.M.; Rorrer, G.L. Cultivation of microplantlets derived from the marine red alga Agardhiella
subulata in a stirred tank photobioreactor. Biotechnol. Prog. 2003, 19, 418–427. [CrossRef]
Mar. Drugs 2020, 18, 170 16 of 22
79. Hahn, T.; Lang, S.; Ulber, R.; Muffler, K. Novel procedures for the extraction of fucoidan from brown algae.
Process Biochem. 2012, 47, 1691–1698. [CrossRef]
80. Thinh, P.D.; Menshova, R.V.; Ermakova, S.P.; Anastyuk, S.D.; Ly, B.M.; Zvyagintseva, T.N.
Structural characteristics and anticancer activity of fucoidan from the brown alga Sargassum mcclurei.
Mar. Drugs 2013, 11, 1456–1476. [CrossRef]
81. De Reviers, B. Fucans and alginates without phenolic compounds. J. Appl. Phycol. 1989, 1, 75–76. [CrossRef]
82. Yang, W.N.; Chen, P.W.; Huang, C.Y. Compositional characteristics and in vitro evaluations of antioxidant
and neuroprotective properties of crude extracts of fucoidan prepared from compressional puffing-pretreated
Sargassum crassifolium. Mar. Drugs 2017, 15, 183. [CrossRef] [PubMed]
83. Zhang, R.; Zhang, X.; Tang, Y.; Mao, J. Composition, isolation, purification and biological activities of
Sargassum fusiforme polysaccharides: A review. Carbohydr. Polym. 2020, 228, 115381. [CrossRef] [PubMed]
84. Spicer, S.E.; Adams, J.M.M.; Thomas, D.S.; Gallagher, J.A.; Winters, A.L. Novel rapid method for the
characterisation of polymeric sugars from macroalgae. J. Appl. Phycol. 2017, 29, 1507–1513. [CrossRef]
85. Zou, P.; Lu, X.; Zhao, H.; Yuan, Y.; Meng, L.; Zhang, C.; Li, Y. Polysaccharides derived from the brown algae
Lessonia nigrescens enhance salt stress tolerance to wheat seedlings by enhancing the antioxidant system and
modulating intracellular ion concentration. Front. Plant Sci. 2019, 10, 48. [CrossRef]
86. Peng, J.; Yuan, J.-P.; Wu, C.-F.; Wang, J.-H. Fucoxanthin, a marine carotenoid present in brown seaweeds and
diatoms: Metabolism and bioactivities relevant to human health. Mar. Drugs 2011, 9, 1806–1828. [CrossRef]
87. Da Costa, E.; Domingues, P.; Melo, T.; Coelho, E.; Pereira, R.; Calado, R.; Abreu, M.H.; Domingues, M.R.
Lipidomic signatures reveal seasonal shifts on the relative abundance of high-valued lipids from the brown
algae Fucus vesiculosus. Mar. Drugs 2019, 17, 335. [CrossRef]
88. Terasaki, M.; Hirose, A.; Narayan, B.; Baba, Y.; Kawagoe, C.; Yasui, H.; Saga, N.; Hosokawa, M.; Miyashita, K.
Evaluation of recoverable functional lipid components of several brown seaweeds (Phaeophyta) from Japan
with special reference to fucoxanthin and fucosterol contents. J. Phycol. 2009, 45, 974–980. [CrossRef]
89. Zhu, F. Interactions between cell wall polysaccharides and polyphenols. Crit. Rev. Food Sci. Nutr. 2018, 58,
1808–1831. [CrossRef]
90. Li, Y.; Fu, X.; Duan, D.; Liu, X.; Xu, J.; Gao, X. Extraction and Identification of Phlorotannins from the Brown
Alga, Sargassum fusiforme (Harvey) Setchell. Mar. Drugs 2017, 15, 49. [CrossRef]
91. Bertoni, G. A key step in phlorotannin biosynthesis revealed. Plant Cell 2013, 25, 2770. [CrossRef] [PubMed]
92. Catarino, M.D.; Silva, A.M.S.; Cardoso, S.M. Fucaceae: A source of bioactive phlorotannins. Int. J. Mol. Sci.
2017, 18, 1327. [CrossRef] [PubMed]
93. Thomas, N.V.; Kim, S.K. Potential pharmacological applications of polyphenolic derivatives from marine
brown algae. Environ. Toxicol. Pharmacol. 2011, 32, 325–335. [CrossRef] [PubMed]
94. Agregán, R.; Munekata, P.E.S.; Franco, D.; Carballo, J.; Barba, F.J.; Lorenzo, J.M. Antioxidant potential
of extracts obtained from macro- (Ascophyllum nodosum, Fucus vesiculosus and Bifurcaria bifurcata) and
micro-Algae (Chlorella vulgaris and Spirulina platensis) assisted by ultrasound. Medicines 2018, 5, 33.
95. Zhang, M.Y.; Guo, J.; Hu, X.M.; Zhao, S.Q.; Li, S.L.; Wang, J. An in vivo anti-tumor effect of eckol from marine
brown algae by improving the immune response. Food Funct. 2019, 10, 4361–4371. [CrossRef]
96. Gall, E.A.; Lelchat, F.; Hupel, M.; Jégou, C.; Stiger-Pouvreau, V. Extraction and purification of phlorotannins
from brown algae. In Natural Products from Marine Algae: Methods and Protocols; Stengel, D.B., Connan, S.,
Eds.; Springer: New York, NY, USA, 2015; pp. 131–143.
97. Brzonova, I.; Kozliak, E.I.; Andrianova, A.A.; LaVallie, A.; Kubátová, A.; Ji, Y. Production of lignin based
insoluble polymers (anionic hydrogels) by C. versicolor. Sci. Rep. 2017, 7, 17507. [CrossRef]
98. Hahn, T.; Zayed, A.; Kovacheva, M.; Stadtmüller, R.; Lang, S.; Muffler, K.; Ulber, R. Dye affinity
chromatography for fast and simple purification of fucoidan from marine brown algae. Eng. Life Sci.
2016, 16, 78–87. [CrossRef]
99. Chades, T.; Scully, S.M.; Ingvadottir, E.M.; Orlygsson, J. Fermentation of mannitol extracts from brown macro
algae by Thermophilic clostridia. Front. Microbiol. 2018, 9, 1931. [CrossRef]
100. Balboa, E.M.; Rivas, S.; Moure, A.; Dominguez, H.; Parajo, J.C. Simultaneous extraction and depolymerization
of fucoidan from Sargassum muticum in aqueous media. Mar. Drugs 2013, 11, 4612–4627. [CrossRef]
101. Descamps, V.; Colin, S.; Lahaye, M.; Jam, M.; Richard, C.; Potin, P.; Barbeyron, T.; Yvin, J.-C.; Kloareg, B.
Isolation and culture of a marine bacterium degrading the sulfated fucans from marine brown algae.
Mar. Biotechnol. 2006, 8, 27–39. [CrossRef]
Mar. Drugs 2020, 18, 170 17 of 22
102. Abdella, A.A.; Ulber, R.; Zayed, A. Chitosan-toluidine blue beads for purification of fucoidans.
Carbohydr. Polym. 2020, 231, 115686. [CrossRef] [PubMed]
103. Kadam, S.U.; Tiwari, B.K.; O’Donnell, C.P. Application of novel extraction technologies for bioactives from
marine algae. J. Agric. Food Chem. 2013, 61, 4667–4675. [CrossRef]
104. Pozharitskaya, O.N.; Shikov, A.N.; Faustova, N.M.; Obluchinskaya, E.D.; Kosman, V.M.; Vuorela, H.;
Makarov, V.G. Pharmacokinetic and tissue distribution of fucoidan from Fucus vesiculosus after oral
administration to rats. Mar. Drugs 2018, 16, 132. [CrossRef] [PubMed]
105. Hadj Ammar, H.; Lajili, S.; Ben Said, R.; Le Cerf, D.; Bouraoui, A.; Majdoub, H. Physico-chemical
characterization and pharmacological evaluation of sulfated polysaccharides from three species of
Mediterranean brown algae of the genus Cystoseira. DARU J. Pharm. Sci. 2015, 23, 1. [CrossRef]
[PubMed]
106. Zhang, Y.; Xu, M.; Hu, C.; Liu, A.; Chen, J.; Gu, C.; Zhang, X.; You, C.; Tong, H.; Wu, M.; et al.
Sargassum fusiforme fucoidan SP2 extends the lifespan of Drosophila melanogaster by upregulating the
Nrf2-mediated antioxidant signaling pathway. Oxidative Med. Cell. Longev. 2019, 2019, 8918914. [CrossRef]
107. Saepudin, E.; Sinurat, E.; Suryabrata, I.A. Depigmentation and characterization of fucoidan from brown
seaweed Sargassum binderi Sonder. IOP Conference Series: Mater. Sci. Eng. 2018, 299, 012027. [CrossRef]
108. Patel, A.; Mikes, F.; Matsakas, L. An overview of current pretreatment methods used to improve lipid
extraction from Oleaginous micro-organisms. Molecules 2018, 23, 1562. [CrossRef]
109. Huang, C.-Y.; Kuo, C.-H.; Chen, P.-W. Compressional-puffing pretreatment enhances neuroprotective effects
of fucoidans from the brown seaweed Sargassum hemiphyllum on 6-hydroxydopamine-induced apoptosis in
SH-SY5Y cells. Molecules 2017, 23, 78. [CrossRef]
110. Huang, C.-Y.; Wu, S.-J.; Yang, W.-N.; Kuan, A.-W.; Chen, C.-Y. Antioxidant activities of crude extracts of
fucoidan extracted from Sargassum glaucescens by a compressional-puffing-hydrothermal extraction process.
Food Chem. 2016, 197, 1121–1129. [CrossRef]
111. Kordjazi, M.; Shabanpour, B.; Zabihi, E.; Faramarzi, M.A.; Feizi, F.; Ahmadi Gavlighi, H.; Feghhi, M.A.;
Hosseini, S.A. Sulfated polysaccharides purified from two species of Padina improve collagen and epidermis
formation in the rat. Int. J. Mol. Cell. Med. 2013, 2, 156–163.
112. Cho, M.L.; Lee, B.-Y.; You, S.G. Relationship between oversulfation and conformation of low and high
molecular weight fucoidans and evaluation of their in vitro anticancer activity. Molecules 2010, 16, 291–297.
[CrossRef] [PubMed]
113. Oliveira, R.M.; Câmara, R.B.G.; Monte, J.F.S.; Viana, R.L.S.; Melo, K.R.T.; Queiroz, M.F.; Filgueira, L.G.A.;
Oyama, L.M.; Rocha, H.A.O. Commercial fucoidans from Fucus vesiculosus can be grouped into antiadipogenic
and adipogenic agents. Mar. Drugs 2018, 16, 193. [CrossRef] [PubMed]
114. Kusaykin, M.I.; Silchenko, A.S.; Zakharenko, A.M.; Zvyagintseva, T.N. Fucoidanases. Glycobiology 2015, 26,
3–12. [CrossRef] [PubMed]
115. Ale, M.T.; Meyer, A.S. Fucoidans from brown seaweeds: An update on structures, extraction techniques and
use of enzymes as tools for structural elucidation. RSC Adv. 2013, 3, 8131–8141. [CrossRef]
116. Huang, C.-Y.; Kuo, C.-H.; Lee, C.-H. Antibacterial and antioxidant capacities and attenuation
of lipid accumulation in 3T3-L1 adipocytes by low-molecular-weight fucoidans prepared from
compressional-puffing-pretreated Sargassum crassifolium. Mar. Drugs 2018, 16, 24. [CrossRef] [PubMed]
117. Imbs, T.I.; Shevchenko, N.M.; Sukhoverkhov, S.V.; Semenova, T.L.; Skriptsova, A.V.; Zvyagintseva, T.N.
Seasonal variations of the composition and structural characteristics of polysaccharides from the brown alga
Costaria costata. Chem. Nat. Compd. 2009, 45, 786–791. [CrossRef]
118. Fidelis, G.P.; Silva, C.H.F.; Nobre, L.; Medeiros, V.P.; Rocha, H.A.O.; Costa, L.S. Antioxidant fucoidans
obtained from tropical seaweed protect pre-osteoblastic cells from hydrogen peroxide-induced damage.
Mar. Drugs 2019, 17, 506. [CrossRef]
119. Rohwer, K.; Neupane, S.; Bittkau, K.S.; Galarza Perez, M.; Dorschmann, P.; Roider, J.; Alban, S.; Klettner, A.
Effects of Crude Fucus distichus Subspecies evanescens Fucoidan Extract on Retinal Pigment Epithelium
Cells-Implications for Use in Age-Related Macular Degeneration. Mar. Drugs 2019, 17, 538. [CrossRef]
120. Rodriguez-Jasso, R.M.; Mussatto, S.I.; Pastrana, L.; Aguilar, C.N.; Teixeira, J.A. Microwave-assisted extraction
of sulfated polysaccharides (fucoidan) from brown seaweed. Carbohydr. Polym. 2011, 86, 1137–1144.
[CrossRef]
Mar. Drugs 2020, 18, 170 18 of 22
121. Mussatto, S.I. Microwave-assisted extraction of fucoidan from marine algae. In Natural Products from Marine
Algae: Methods and Protocols; Stengel, D.B., Connan, S., Eds.; Springer: New York, NY, USA, 2015; pp. 151–157.
122. Alboofetileh, M.; Rezaei, M.; Tabarsa, M.; You, S. Ultrasound-assisted extraction of sulfated polysaccharide
from Nizamuddinia zanardinii: Process optimization, structural characterization, and biological properties.
J. Food Process Eng. 2019, 42, e12979. [CrossRef]
123. Garcia-Vaquero, M.; O’Doherty, J.V.; Tiwari, B.K.; Sweeney, T.; Rajauria, G. Enhancing the extraction
of polysaccharides and antioxidants from macroalgae using sequential hydrothermal-assisted extraction
followed by ultrasound and thermal technologies. Mar. Drugs 2019, 17, 457. [CrossRef] [PubMed]
124. Alboofetileh, M.; Rezaei, M.; Tabarsa, M.; You, S.; Mariatti, F.; Cravotto, G. Subcritical water extraction
as an efficient technique to isolate biologically-active fucoidans from Nizamuddinia zanardinii. Int. J. Biol.
Macromol. 2019, 128, 244–253. [CrossRef] [PubMed]
125. Qin, Y.; Yuan, Q.; Zhang, Y.; Li, J.; Zhu, X.; Zhao, L.; Wen, J.; Liu, J.; Zhao, L.; Zhao, J. Enzyme-assisted
extraction optimization, characterization and antioxidant activity of polysaccharides from sea cucumber
Phyllophorus proteus. Molecules 2018, 23, 590. [CrossRef]
126. Wijesinghe, W.A.; Jeon, Y.J. Enzyme-assistant extraction (EAE) of bioactive components: A useful approach
for recovery of industrially important metabolites from seaweeds: A review. Fitoterapia 2012, 83, 6–12.
[CrossRef]
127. Ahn, G.; Lee, W.; Kim, K.-N.; Lee, J.-H.; Heo, S.-J.; Kang, N.; Lee, S.-H.; Ahn, C.-B.; Jeon, Y.-J. A sulfated
polysaccharide of Ecklonia cava inhibits the growth of colon cancer cells by inducing apoptosis. EXCLI J.
2015, 14, 294–306.
128. Badrinathan, S.; Shiju, T.M.; Sharon Christa, A.S.; Arya, R.; Pragasam, V. Purification and structural
characterization of sulfated polysaccharide from Sargassum myriocystum and its efficacy in scavenging free
radicals. Indian J. Pharm. Sci. 2012, 74, 549–555. [PubMed]
129. Liu, Y.; Huang, G. Extraction and derivatisation of active polysaccharides. J. Enzym. Inhib. Med. Chem. 2019,
34, 1690–1696. [CrossRef]
130. Zhao, D.; Xu, J.; Xu, X. Bioactivity of fucoidan extracted from Laminaria japonica using a novel procedure
with high yield. Food Chem. 2018, 245, 911–918. [CrossRef]
131. Xing, R.; Liu, S.; Yu, H.; Chen, X.; Qin, Y.; Li, K.; Li, P. Extraction and separation of fucoidan from Laminaria
japonica with chitosan as extractant. BioMed Res. Int. 2013, 2013, 193689. [CrossRef]
132. Ertani, A.; Francioso, O.; Tinti, A.; Schiavon, M.; Pizzeghello, D.; Nardi, S. Evaluation of seaweed extracts
from Laminaria and Ascophyllum nodosum spp. as biostimulants in Zea mays L. using a combination of
chemical, biochemical and morphological approaches. Front. Plant Sci. 2018, 9, 428. [CrossRef]
133. Lee, J.M.; Oh, S.Y.; Johnston, T.V.; Ku, S.; Ji, G.E. Biocatalysis of fucodian in Undaria pinnatifida sporophyll
using Bifidobacterium longum RD47 for production of prebiotic fucosylated oligosaccharide. Mar. Drugs 2019,
17, 117. [CrossRef] [PubMed]
134. Somasundaram, S.N.; Shanmugam, S.; Subramanian, B.; Jaganathan, R. Cytotoxic effect of fucoidan extracted
from Sargassum cinereum on colon cancer cell line HCT-15. Int. J. Biol. Macromol. 2016, 91. [CrossRef]
[PubMed]
135. Ustyuzhanina, N.E.; Ushakova, N.A.; Zyuzina, K.A.; Bilan, M.I.; Elizarova, A.L.; Somonova, O.V.;
Madzhuga, A.V.; Krylov, V.B.; Preobrazhenskaya, M.E.; Usov, A.I.; et al. Influence of fucoidans on
hemostatic system. Mar. Drugs 2013, 11, 2444–2458. [CrossRef] [PubMed]
136. Saboural, P.; Chaubet, F.; Rouzet, F.; Al-Shoukr, F.; Azzouna, R.B.; Bouchemal, N.; Picton, L.; Louedec, L.;
Maire, M.; Rolland, L.; et al. Purification of a low molecular weight fucoidan for SPECT molecular imaging
of myocardial infarction. Mar. Drugs 2014, 12, 4851–4867. [CrossRef] [PubMed]
137. Garcia-Vaquero, M.; Rajauria, G.; O’Doherty, J.V.; Sweeney, T. Polysaccharides from macroalgae:
Recent advances, innovative technologies and challenges in extraction and purification. Food Res. Int. 2017,
99, 1011–1020. [CrossRef]
138. Hahn, T.; Schulz, M.; Stadtmüller, R.; Zayed, A.; Muffler, K.; Lang, S.; Ulber, R. Cationic dye for the specific
determination of sulfated polysaccharides. Anal. Lett. 2016, 49, 1948–1962. [CrossRef]
139. Lee, J.M.; Shin, Z.U.; Mavlonov, G.T.; Abdurakhmonov, I.Y.; Yi, T.-H. Solid-phase colorimetric method for the
quantification of fucoidan. Appl. Biochem. Biotechnol. 2012, 168, 1019–1024. [CrossRef] [PubMed]
Mar. Drugs 2020, 18, 170 19 of 22
140. Palanisamy, S.; Vinosha, M.; Manikandakrishnan, M.; Anjali, R.; Rajasekar, P.; Marudhupandi, T.;
Manikandan, R.; Vaseeharan, B.; Prabhu, N.M. Investigation of antioxidant and anticancer potential
of fucoidan from Sargassum polycystum. Int. J. Biol. Macromol. 2018, 116, 151–161. [CrossRef]
141. Cong, Q.; Chen, H.; Liao, W.; Xiao, F.; Wang, P.; Qin, Y.; Dong, Q.; Ding, K. Structural characterization and
effect on anti-angiogenic activity of a fucoidan from Sargassum fusiforme. Carbohydr. Polym. 2016, 136,
899–907. [CrossRef]
142. Li, G.; Row, K.H. Magnetic molecularly imprinted polymers for recognition and enrichment of polysaccharides
from seaweed. J. Sep. Sci. 2017, 40, 4765–4772. [CrossRef]
143. Guthrie, L.; Wolfson, S.; Kelly, L. The human gut chemical landscape predicts microbe-mediated
biotransformation of foods and drugs. eLife 2019, 8, e42866. [CrossRef] [PubMed]
144. Wang, J.; Zhang, Q.; Zhang, Z.; Song, H.; Li, P. Potential antioxidant and anticoagulant capacity of low
molecular weight fucoidan fractions extracted from Laminaria japonica. Int. J. Biol. Macromol. 2010, 46, 6–12.
[CrossRef] [PubMed]
145. Lee, J.B.; Hayashi, K.; Hashimoto, M.; Nakano, T.; Hayashi, T. Novel antiviral fucoidan from sporophyll of
Undaria pinnatifida (Mekabu). Chem. Pharm. Bull. 2004, 52, 1091–1094. [CrossRef] [PubMed]
146. Elizondo-Gonzalez, R.; Cruz-Suarez, L.E.; Ricque-Marie, D.; Mendoza-Gamboa, E.; Rodriguez-Padilla, C.;
Trejo-Avila, L.M. In vitro characterization of the antiviral activity of fucoidan from Cladosiphon okamuranus
against Newcastle disease virus. Virol. J. 2012, 9, 307. [CrossRef]
147. Jeong, J.-W.; Hwang, S.J.; Han, M.H.; Lee, D.-S.; Yoo, J.S.; Choi, I.-W.; Cha, H.-J.; Kim, S.; Kim, H.-S.; Kim, G.-Y.;
et al. Fucoidan inhibits lipopolysaccharide-induced inflammatory responses in RAW 264.7 macrophages
and zebrafish larvae. Mol. Cell. Toxicol. 2017, 13, 405–417. [CrossRef]
148. Klettner, A. Fucoidan as a potential therapeutic for major blinding diseases - a hypothesis. Mar. Drugs 2016,
14, 31. [CrossRef]
149. Barbosa, A.I.; Coutinho, A.J.; Costa Lima, S.A.; Reis, S. Marine polysaccharides in pharmaceutical applications:
Fucoidan and chitosan as key players in the drug delivery match field. Mar. Drugs 2019, 17, 654. [CrossRef]
150. Wang, P.; Kankala, R.K.; Fan, J.; Long, R.; Liu, Y.; Wang, S. Poly-L-ornithine/fucoidan-coated calcium
carbonate microparticles by layer-by-layer self-assembly technique for cancer theranostics. J. Mater. Sci.
Mater. Med. 2018, 29, 68. [CrossRef]
151. Wang, X.; Shan, X.; Dun, Y.; Cai, C.; Hao, J.; Li, G.; Cui, K.; Yu, G. Anti-metabolic syndrome effects of fucoidan
from Fucus vesiculosus via reactive oxygen species-mediated regulation of JNK, Akt, and AMPK signaling.
Molecules 2019, 24, 3319. [CrossRef]
152. Sharma, G.; Kar, S.; Basu Ball, W.; Ghosh, K.; Das, P.K. The curative effect of fucoidan on visceral leishmaniasis
is mediated by activation of MAP kinases through specific protein kinase C isoforms. Cell. Mol. Immunol.
2014, 11, 263–274. [CrossRef]
153. Varikuti, S.; Jha, B.K.; Volpedo, G.; Ryan, N.M.; Halsey, G.; Hamza, O.M.; McGwire, B.S.; Satoskar, A.R.
Host-directed drug therapies for neglected tropical diseases caused by protozoan parasites. Front. Microbiol.
2018, 9, 2655. [CrossRef] [PubMed]
154. Jin, J.O.; Zhang, W.; Du, J.Y.; Wong, K.W.; Oda, T.; Yu, Q. Fucoidan can function as an adjuvant in vivo
to enhance dendritic cell maturation and function and promote antigen-specific T cell immune responses.
PLoS ONE 2014, 9, e99396. [CrossRef] [PubMed]
155. Tabarsa, M.; Dabaghian, E.H.; You, S.; Yelithao, K.; Cao, R.; Rezaei, M.; Alboofetileh, M.; Bita, S. The activation
of NF-κB and MAPKs signaling pathways of RAW264.7 murine macrophages and natural killer cells by
fucoidan from Nizamuddinia zanardinii. Int. J. Biol. Macromol. 2020, 148, 56–67. [CrossRef] [PubMed]
156. Wang, P.; Liu, Z.; Liu, X.; Teng, H.; Zhang, C.; Hou, L.; Zou, X. Anti-metastasis effect of fucoidan from Undaria
pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells. PLoS ONE 2014, 9, e106071. [CrossRef]
[PubMed]
157. Li, Y.; Zhao, W.; Wang, L.; Chen, Y.; Zhang, H.; Wang, T.; Yang, X.; Xing, F.; Yan, J.; Fang, X. Protective effects of
fucoidan against hydrogen peroxide-induced oxidative damage in porcine intestinal epithelial cells. Animals
2019, 9, 1108. [CrossRef]
158. Chen, J.H.; Lim, J.D.; Sohn, E.H.; Choi, Y.S.; Han, E.T. Growth-inhibitory effect of a fucoidan from brown
seaweed Undaria pinnatifida on Plasmodium parasites. Parasitol. Res. 2009, 104, 245–250. [CrossRef]
159. Jia, Y.; Sun, Y.; Weng, L.; Li, Y.; Zhang, Q.; Zhou, H.; Yang, B. Low molecular weight fucoidan protects renal
tubular cells from injury induced by albumin overload. Sci. Rep. 2016, 6, 31759. [CrossRef]
Mar. Drugs 2020, 18, 170 20 of 22
160. Chen, C.-H.; Sue, Y.-M.; Cheng, C.-Y.; Chen, Y.-C.; Liu, C.-T.; Hsu, Y.-H.; Hwang, P.-A.; Huang, N.-J.;
Chen, T.-H. Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway.
Sci. Rep. 2017, 7, 40183. [CrossRef]
161. Abdel-Daim, M.M.; Abushouk, A.I.; Bahbah, E.I.; Bungău, S.G.; Alyousif, M.S.; Aleya, L.; Alkahtani, S.
Fucoidan protects against subacute diazinon-induced oxidative damage in cardiac, hepatic, and renal tissues.
Environ. Sci. Pollut. Res. 2020. Online ahead of print. [CrossRef]
162. Chen, M.-C.; Hsu, W.-L.; Hwang, P.-A.; Chou, T.-C. Low molecular weight fucoidan inhibits tumor
angiogenesis through downregulation of HIF-1/VEGF signaling under hypoxia. Mar. Drugs 2015, 13,
4436–4451. [CrossRef]
163. Marinval, N.; Saboural, P.; Haddad, O.; Maire, M.; Bassand, K.; Geinguenaud, F.; Djaker, N.; Ben Akrout, K.;
Lamy de la Chapelle, M.; Robert, R.; et al. Identification of a pro-angiogenic potential and cellular uptake
mechanism of a LMW highly sulfated fraction of fucoidan from Ascophyllum nodosum. Mar. Drugs 2016, 14,
185. [CrossRef] [PubMed]
164. Cheng, Y.; Sibusiso, L.; Hou, L.; Jiang, H.; Chen, P.; Zhang, X.; Wu, M.; Tong, H. Sargassum fusiforme fucoidan
modifies the gut microbiota during alleviation of streptozotocin-induced hyperglycemia in mice. Int. J. Biol.
Macromol. 2019, 131, 1162–1170. [CrossRef] [PubMed]
165. Li, B.; Juenet, M.; Aid-Launais, R.; Maire, M.; Ollivier, V.; Letourneur, D.; Chauvierre, C. Development of
polymer microcapsules functionalized with fucoidan to target p-selectin overexpressed in cardiovascular
diseases. Adv. Healthc. Mater. 2017, 6, 1601200. [CrossRef] [PubMed]
166. Kim, Y.-I.; Oh, W.-S.; Song, P.H.; Yun, S.; Kwon, Y.-S.; Lee, Y.J.; Ku, S.-K.; Song, C.-H.; Oh, T.-H. Anti-photoaging
effects of low molecular-weight fucoidan on ultraviolet B-irradiated mice. Mar. Drugs 2018, 16, 286. [CrossRef]
[PubMed]
167. Kim, J.H.; Lee, J.-E.; Kim, K.H.; Kang, N.J. Beneficial effects of marine algae-derived carbohydrates for skin
health. Mar. Drugs 2018, 16, 459. [CrossRef]
168. Fitton, J.H.; Dell’Acqua, G.; Gardiner, V.-A.; Karpiniec, S.S.; Stringer, D.N.; Davis, E. Topical benefits of two
fucoidan-rich extracts from marine macroalgae. Cosmetics 2015, 2, 66–81. [CrossRef]
169. Song, Y.S.; Li, H.; Balcos, M.C.; Yun, H.-Y.; Baek, K.J.; Kwon, N.S.; Choi, H.-R.; Park, K.-C.; Kim, D.-S.
Fucoidan promotes the reconstruction of skin equivalents. Korean J. Physiol. Pharmacol. 2014, 18, 327–331.
[CrossRef]
170. Venkatesan, J.; Anil, S.; Kim, S.-K.; Shim, M.S. Seaweed polysaccharide-based nanoparticles: Preparation
and applications for drug delivery. Polymers 2016, 8, 30. [CrossRef]
171. Pinheiro, A.C.; Bourbon, A.I.; Cerqueira, M.A.; Maricato, É.; Nunes, C.; Coimbra, M.A.; Vicente, A.A.
Chitosan/fucoidan multilayer nanocapsules as a vehicle for controlled release of bioactive compounds.
Carbohydr. Polym. 2015, 115, 1–9. [CrossRef]
172. Choi, D.G.; Venkatesan, J.; Shim, M.S. Selective anticancer therapy using pro-oxidant drug-loaded
chitosan-fucoidan nanoparticles. Int. J. Mol. Sci. 2019, 20, 3220. [CrossRef]
173. Tsai, M.-h.; Chuang, C.-c.; Chen, C.-c.; Yen, H.-j.; Cheng, K.-m.; Chen, X.-a.; Shyu, H.-f.; Lee, C.-y.; Young, J.-j.;
Kau, J.-h. Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant:
In vitro and in vivo efficacy in comparison to CpG. Carbohydr. Polym. 2020, 236, 116041. [CrossRef]
174. Venkatesan, J.; Singh, S.K.; Anil, S.; Kim, S.-K.; Shim, M.S. Preparation, characterization and biological
applications of biosynthesized silver nanoparticles with chitosan-fucoidan coating. Molecules 2018, 23, 1429.
[CrossRef]
175. Hwang, P.-A.; Yan, M.-D.; Lin, H.-T.V.; Li, K.-L.; Lin, Y.-C. Toxicological evaluation of low molecular weight
fucoidan in vitro and in vivo. Mar. Drugs 2016, 14, 121. [CrossRef] [PubMed]
176. Zhu, Z.; Zhu, B.; Ai, C.; Lu, J.; Wu, S.; Liu, Y.; Wang, L.; Yang, J.; Song, S.; Liu, X. Development and application
of a HPLC-MS/MS method for quantitation of fucosylated chondroitin sulfate and fucoidan in sea cucumbers.
Carbohydr. Res. 2018, 466, 11–17. [CrossRef] [PubMed]
177. Yu, L.; Xue, C.; Chang, Y.; Xu, X.; Ge, L.; Liu, G.; Wang, Y. Structure elucidation of fucoidan composed of
a novel tetrafucose repeating unit from sea cucumber Thelenota ananas. Food Chem. 2014, 146, 113–119.
[CrossRef]
178. Zhao, X.; Guo, F.; Hu, J.; Zhang, L.; Xue, C.; Zhang, Z.; Li, B. Antithrombotic activity of oral administered
low molecular weight fucoidan from Laminaria Japonica. Thromb. Res. 2016, 144, 46–52. [CrossRef]
Mar. Drugs 2020, 18, 170 21 of 22
179. Tsai, H.L.; Tai, C.J.; Huang, C.W.; Chang, F.R.; Wang, J.Y. Efficacy of low-molecular-weight fucoidan as
a supplemental therapy in metastatic colorectal cancer patients: A double-blind randomized controlled trial.
Mar. Drugs 2017, 15, 122. [CrossRef]
180. Jonsson, M.; Allahgholi, L.; Sardari, R.R.R.; Hreggviethsson, G.O.; Nordberg Karlsson, E. Extraction and
modification of macroalgal polysaccharides for current and next-generation applications. Molecules 2020, 25,
930. [CrossRef] [PubMed]
181. Cumashi, A.; Ushakova, N.A.; Preobrazhenskaya, M.E.; D’Incecco, A.; Piccoli, A.; Totani, L.; Tinari, N.;
Morozevich, G.E.; Berman, A.E.; Bilan, M.I.; et al. A comparative study of the anti-inflammatory, anticoagulant,
antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology
2007, 17, 541–552. [CrossRef] [PubMed]
182. Silchenko, A.S.; Ustyuzhanina, N.E.; Kusaykin, M.I.; Krylov, V.B.; Shashkov, A.S.; Dmitrenok, A.S.;
Usoltseva, R.V.; Zueva, A.O.; Nifantiev, N.E.; Zvyagintseva, T.N. Expression and biochemical characterization
and substrate specificity of the fucoidanase from Formosa algae. Glycobiology 2017, 27, 254–263.
183. Silchenko, A.S.; Rasin, A.B.; Kusaykin, M.I.; Kalinovsky, A.I.; Miansong, Z.; Changheng, L.; Malyarenko, O.;
Zueva, A.O.; Zvyagintseva, T.N.; Ermakova, S.P. Structure, enzymatic transformation, anticancer activity of
fucoidan and sulphated fucooligosaccharides from Sargassum horneri. Carbohydr. Polym. 2017, 175, 654–660.
[CrossRef] [PubMed]
184. Colin, S.; Deniaud, E.; Jam, M.; Descamps, V.; Chevolot, Y.; Kervarec, N.; Yvin, J.C.; Barbeyron, T.; Michel, G.;
Kloareg, B. Cloning and biochemical characterization of the fucanase FcnA: Definition of a novel glycoside
hydrolase family specific for sulfated fucans. Glycobiology 2006, 16, 1021–1032. [CrossRef] [PubMed]
185. Nagao, T.; Arai, Y.; Yamaoka, M.; Komatsu, F.; Yagi, H.; Suzuki, H.; Ohshiro, T. Identification and
characterization of the fucoidanase gene from Luteolibacter algae H18. J. Biosci. Bioeng. 2018, 126, 567–572.
[CrossRef] [PubMed]
186. Bakunina, I.; Nedashkovskaia, O.I.; Alekseeva, S.A.; Ivanova, E.P.; Romanenko, L.A.; Gorshkova, N.M.;
Isakov, V.V.; Zviagintseva, T.N.; Mikhailov, V.V. Degradation of fucoidan by the marine proteobacterium
Pseudoalteromonas citrea. Mikrobiologiia 2002, 71, 49–55. [PubMed]
187. Wu, Q.; Zhang, M.; Wu, K.; Liu, B.; Cai, J.; Pan, R. Purification and characteristics of fucoidanase obtained
from Dendryphiella arenaria TM94. J. Appl. Phycol. 2011, 23, 197–203. [CrossRef]
188. Sakai, T.; Kimura, H.; Kojima, K.; Shimanaka, K.; Ikai, K.; Kato, I. Marine bacterial sulfated
fucoglucuronomannan (SFGM) lyase digests brown algal SFGM into trisaccharides. Mar. Biotechnol.
2003, 5, 70–78. [CrossRef]
189. Sakai, T.; Ishizuka, K.; Shimanaka, K.; Ikai, K.; Kato, I. Structures of oligosaccharides derived from
Cladosiphon okamuranus fucoidan by digestion with marine bacterial enzymes. Mar. Biotechnol. 2003, 5,
536–544.
190. Ohshiro, T.; Ohmoto, Y.; Ono, Y.; Ohkita, R.; Miki, Y.; Kawamoto, H.; Izumi, Y. Isolation and characterization
of a novel fucoidan-degrading microorganism. Biosci. Biotechnol. Biochem. 2010, 74, 1729–1732. [CrossRef]
191. Bilan, M.I.; Kusaykin, M.I.; Grachev, A.A.; Tsvetkova, E.A.; Zvyagintseva, T.N.; Nifantiev, N.E.; Usov, A.I.
Effect of enzyme preparation from the marine mollusk Littorina kurila on fucoidan from the brown alga Fucus
distichus. Biochemistry 2005, 70, 1321–1326. [CrossRef]
192. Kim, W.J.; Kim, S.M.; Lee, Y.H.; Kim, H.G.; Kim, H.K.; Moon, S.H.; Suh, H.H.; Jang, K.H.; Park, Y.I.
Isolation and characterization of marine bacterial strain degrading fucoidan from korean Undaria pinnatifida
Sporophylls. J. Microbiol. Biotechnol. 2008, 18, 616–623.
193. Kim, W.J.; Park, J.W.; Park, J.K.; Choi, D.J.; Park, Y.I. Purification and characterization of a fucoidanase (FNase
S) from a marine bacterium Sphingomonas paucimobilis PF-1. Mar. Drugs 2015, 13, 4398–4417. [CrossRef]
194. Kitamura, K.; Matsuo, M.; Tsuneo, Y. Enzymic degradation of fucoidan by fucoidanase from the
hepatopancreas of Patinopecten yessoensis. Biosci. Biotechnol. Biochem. 1992, 56, 490–494. [CrossRef]
195. Daniel, R.; Berteau, O.; Chevolot, L.; Varenne, A.; Gareil, P.; Goasdoue, N. Regioselective desulfation of
sulfated l-fucopyranoside by a new sulfoesterase from the marine mollusk Pecten maximus. Eur. J. Biochem.
2001, 268, 5617–5626. [CrossRef]
196. Berteau, O.; McCort, I.; Goasdoué, N.; Tissot, B.; Daniel, R. Characterization of a new alpha-L-fucosidase
isolated from the marine mollusk Pecten maximus that catalyzes the hydrolysis of alpha-L-fucose from algal
fucoidan (Ascophyllum nodosum). Glycobiology 2002, 12, 273–282. [CrossRef]
Mar. Drugs 2020, 18, 170 22 of 22
197. Dong, S.; Chang, Y.; Shen, J.; Xue, C.; Chen, F. Purification, expression and characterization of a novel
α-l-fucosidase from a marine bacteria Wenyingzhuangia fucanilytica. Protein Expr. Purif. 2017, 129, 9–17.
[CrossRef]
198. Tanaka, R.; Mizutani, Y.; Shibata, T.; Miyake, H.; Iehata, S.; Mori, T.; Kuroda, K.; Ueda, M. Genome sequence
of Formosa haliotis strain MA1, a brown alga-degrading bacterium isolated from the gut of Abalone Haliotis
gigantea. Genome Announc. 2016, 4, e01312-16. [CrossRef]
199. Chen, F.; Chang, Y.; Dong, S.; Xue, C. Wenyingzhuangia fucanilytica sp. nov., a sulfated fucan utilizing
bacterium isolated from shallow coastal seawater. Int. J. Syst. Evol. Microbiol. 2016, 66, 3270–3275. [CrossRef]
200. Li, J.; Cheng, Y.; Wang, D.; Li, J.; Wang, Y.; Han, W.; Li, F. Draft genome sequence of the
polysaccharide-degrading marine bacterium Pseudoalteromonas sp. Strain A601. Genome Announc. 2017, 5,
e00590-17. [CrossRef]
201. Cao, H.T.T.; Mikkelsen, M.D.; Lezyk, M.J.; Bui, L.M.; Tran, V.T.T.; Silchenko, A.S.; Kusaykin, M.I.; Pham, T.D.;
Truong, B.H.; Holck, J.; et al. Novel enzyme actions for sulphated galactofucan depolymerisation and a new
engineering strategy for molecular stabilisation of fucoidan degrading enzymes. Mar. Drugs 2018, 16, 422.
[CrossRef]
202. Tran, P.H.L.; Duan, W.; Tran, T.T.D. Fucoidan-based nanostructures: A focus on its combination with chitosan
and the surface functionalization of metallic nanoparticles for drug delivery. Int. J. Pharm. 2019, 575, 118956.
[CrossRef]
203. Jesumani, V.; Du, H.; Pei, P.; Aslam, M.; Huang, N. Comparative study on skin protection activity of
polyphenol-rich extract and polysaccharide-rich extract from Sargassum vachellianum. PLoS ONE 2020, 15,
e0227308. [CrossRef] [PubMed]
204. Brunt, E.G.; Burgess, J.G. The promise of marine molecules as cosmetic active ingredients. Int. J. Cosmet. Sci.
2018, 40, 1–15. [CrossRef] [PubMed]
205. Ferreira, R.M.; Ramalho Ribeiro, A.; Patinha, C.; Silva, A.M.S.; Cardoso, S.M.; Costa, R. Water extraction
kinetics of bioactive compounds of Fucus vesiculosus. Molecules 2019, 24, 3408. [CrossRef] [PubMed]
206. Michel, G.; Tonon, T.; Scornet, D.; Cock, J.M.; Kloareg, B. The cell wall polysaccharide metabolism of the
brown alga Ectocarpus siliculosus. Insights into the evolution of extracellular matrix polysaccharides in
eukaryotes. New Phytol. 2010, 188, 82–97. [CrossRef]
207. Chi, S.; Liu, T.; Wang, X.; Wang, R.; Wang, S.; Wang, G.; Shan, G.; Liu, C. Functional genomics analysis reveals
the biosynthesis pathways of important cellular components (alginate and fucoidan) of Saccharina. Curr.
Genet. 2018, 64, 259–273. [CrossRef] [PubMed]
208. Shao, Z.; Zhang, P.; Lu, C.; Li, S.; Chen, Z.; Wang, X.; Duan, D. Transcriptome sequencing of Saccharina
Japonica Sporophytes during whole developmental periods reveals regulatory networks underlying alginate
and mannitol biosynthesis. BMC Genom. 2019, 20, 975. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
